Werewolf Therapeutics (NASDAQ:HOWL) Releases Earnings Results, Beats Estimates By $0.15 EPS

Werewolf Therapeutics (NASDAQ:HOWL) released its earnings results on Friday. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.15, FiscalAI reports.

Werewolf Therapeutics Price Performance

Shares of HOWL traded down $0.04 during midday trading on Friday, hitting $0.82. 38,357 shares of the company traded hands, compared to its average volume of 437,892. The firm has a 50 day moving average of $0.69 and a 200-day moving average of $1.03. Werewolf Therapeutics has a 52 week low of $0.53 and a 52 week high of $2.38. The stock has a market cap of $39.75 million, a price-to-earnings ratio of -0.51 and a beta of 0.78. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87.

Wall Street Analysts Forecast Growth

A number of research firms have commented on HOWL. Wedbush cut Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price target on the stock. in a report on Friday, December 19th. Citizens Jmp cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, January 21st. Citigroup cut Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a report on Friday, December 19th. Finally, HC Wainwright dropped their price target on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, December 19th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Werewolf Therapeutics presently has a consensus rating of “Hold” and an average target price of $3.75.

Insider Activity

In related news, Director Luke Evnin sold 58,980 shares of the firm’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $0.57, for a total value of $33,618.60. Following the completion of the transaction, the director directly owned 2,309,869 shares of the company’s stock, valued at approximately $1,316,625.33. This trade represents a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 499,420 shares of company stock valued at $296,825 over the last quarter. Insiders own 23.60% of the company’s stock.

Institutional Investors Weigh In On Werewolf Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in HOWL. Susquehanna International Group LLP lifted its holdings in shares of Werewolf Therapeutics by 16.9% in the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after acquiring an additional 13,439 shares during the last quarter. Vontobel Holding Ltd. grew its holdings in Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after purchasing an additional 24,003 shares during the last quarter. Regal Investment Advisors LLC grew its holdings in Werewolf Therapeutics by 93.3% during the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after purchasing an additional 25,389 shares during the last quarter. Bank of America Corp DE raised its position in Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after purchasing an additional 25,882 shares during the period. Finally, Qube Research & Technologies Ltd purchased a new stake in Werewolf Therapeutics in the 2nd quarter worth about $48,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.